Navigation Links
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Date:1/8/2009

ly there is no marketed treatment for DGF; when DGF is diagnosed the patient is supported with dialysis and other supportive care.

The investigational drug candidate QPI-1002 is a siRNA designed to temporarily inhibit the expression of the pro-apoptotic gene, p53. This siRNA is based on Quark's proprietary, patented therapeutic concept of temporarily inhibiting the expression of p53 to protect normal cells from acute injury. QPI-1002 is a chemically modified siRNA discovered by Quark with structure covered under licenses from Silence Therapeutics and from Alnylam Pharmaceuticals. QPI-1002 was the first systemically administered siRNA in a human clinical study.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to other target tissues including the eye, ear, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery and of delayed graft function in kidney transplantation. QPI-1007, which is a siRNA that utilizes a novel siRNA structure developed by Quark and is being evaluated in advanced IND-e
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
2. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
5. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
9. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... -- Paragon 28, Inc . announced ... foot plating system that supplants the Normed product line ... R3CON PLATING SYSTEM greatly enhances the product offerings of ... TM Screw Systems and Preserve TM Bone ... the GORILLA TM R3CON SYSTEM offers innovative solutions ...
(Date:9/22/2014)... Sept. 22, 2014 The western European ... It is largely a replacement market with fewer ... mergers, acquisitions and partnerships are redefining competitive landscape ... research service provides details about revenue forecasts, unit ... trends across the country. The changing landscape makes ...
(Date:9/22/2014)... 2014 ... the addition of the  "Global Freeze Drying ... Market - Forecast to 2019"  report to ... ,The global freeze drying market was valued ... expected to reach at $2,655.9 million by ...
Breaking Medicine Technology:Paragon 28, Inc. Launches the GORILLA(TM) R3CON PLATING SYSTEM 2Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3Global Freeze Drying / Lyophilization Equipment (Lab, Pilot, & Industrial) Market - Forecast to 2019 2Global Freeze Drying / Lyophilization Equipment (Lab, Pilot, & Industrial) Market - Forecast to 2019 3
... Fla., Nov. 19, 2010 Schizophrenia is a chronic ... the U.S. population and results in substantial medical and ... It also can have devastating health-related and social effects ... A pre-specified analysis from a longer-term clinical ...
... Nov. 19, 2010 Inspiration Biopharmaceuticals, Inc. (Inspiration) ... patients in a pivotal clinical study of OBI-1, ... for the treatment of acquired hemophilia A, a ... a partnership agreement signed with Ipsen SA (Euronext: ...
Cached Medicine Technology:Analysis of Longer-Term Clinical Study Suggests Psychiatric Hospitalization Rates Decreased in Adults with Schizophrenia Treated With INVEGA® SUSTENNA® 2Analysis of Longer-Term Clinical Study Suggests Psychiatric Hospitalization Rates Decreased in Adults with Schizophrenia Treated With INVEGA® SUSTENNA® 3Analysis of Longer-Term Clinical Study Suggests Psychiatric Hospitalization Rates Decreased in Adults with Schizophrenia Treated With INVEGA® SUSTENNA® 4Analysis of Longer-Term Clinical Study Suggests Psychiatric Hospitalization Rates Decreased in Adults with Schizophrenia Treated With INVEGA® SUSTENNA® 5Analysis of Longer-Term Clinical Study Suggests Psychiatric Hospitalization Rates Decreased in Adults with Schizophrenia Treated With INVEGA® SUSTENNA® 6Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A 2Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A 3Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A 4
(Date:9/23/2014)... 2014 Névo takes a bold step ... and adding advanced activity tracking and phone notifications for ... distance, calories burned, and more. , http://www.nevowatch.com ... healthy habits in their busy lives to look and ... that produce healthy results, but until now, style played ...
(Date:9/23/2014)... Positioning themselves as the leading provider of ... products to their basket which customers can get ... name in the market and customers believe in their ... and now customers will get a myriad of best-in-class ... Tactical Safe which uses an authentic military specification weapon ...
(Date:9/22/2014)... The leather seat covers offered by ... company’s professional design team to meet customers’ specific product needs ... selection of Jeep leather seat covers . Furthermore, the ... items. Each product in the new range is now available ... Before the new items are produced, the company’s top designers ...
(Date:9/22/2014)... (FFANY) and leading multimedia retailer QVC recently presented $240,000 ... Cancer Institute (UPCI), partner with UPMC CancerCenter. , The ... QVC Presents "FFANY Shoes on Sale" event, held last ... country, including UPCI for the second year in a ... from this year,s event; the FFANY gala will be ...
(Date:9/22/2014)... On Saturday, September 27, UHY LLP and UHY ... that is doing an amazing job helping kids and refurbishing ... families and friends will be spending the day at Academy ... and graphics, as well as clean the playground and surrounding ... occur in May but due to weather conditions it was ...
Breaking Medicine News(10 mins):Health News:Nevo changes the face of fitness wearables with an analogue watch combining activity tracking, phone notifications, and LED goal progress indicators for active lifestyles 2Health News:Nevo changes the face of fitness wearables with an analogue watch combining activity tracking, phone notifications, and LED goal progress indicators for active lifestyles 3Health News:GunSafes.com Now Offers Secure Tactical Range of Gun Safes 2Health News:Great 2007-2012 Jeep Wrangler JK Real Leather Seat Covers Introduced by Lseat.com 2Health News:Heels for a cause: FFANY, QVC Present $240,000 from shoe sales to Pitt researchers 2Health News:Local CPA Firm Gears Up To Revamp Detroit Elementary School Playground 2Health News:Local CPA Firm Gears Up To Revamp Detroit Elementary School Playground 3
... to 16 years invited to attend on Saturday, April 19th, ... Group today announced the Victorville Youth Soccer Clinic.,They will host ... 9,am - 12 pm at the Eagle Ranch Elementary School., ... 16 and will feature drills, tips,and techniques by AYSO Certified ...
... Products Help Protect and Preserve Buildings, NEW ... and The Energy and Resources Institute (TERI) signed ... of green building design and,certification in India., ... of DuPont India,and Dr. R. K. Pachauri, director ...
... Precision Therapeutics Inc.,a leader in personalized medicine, ... Provider Network (NPPN), PlanCare America (PCA), RMSCO,and ... NY, is one of the largest PPO,networks ... million lives. Their,list of clients includes multi-state ...
... Simulator Experience on eBay, CHICAGO, April 8, ... in the captain,s seat in the fight against ... United is auctioning off a,behind-the-scenes tour and flight ... in Denver, Colo., including two domestic,roundtrip tickets to ...
... fight MS, cancer and heart disease, studies suggest , , ... and tart cherries may guard against multiple sclerosis, cancer ... three findings, which confirm the healthy properties of these ... 2008 meeting in San Diego. , Caffeine appears to ...
... care settings, sophisticated information technology (IT) systems assist in ... adherence to clinical guidelines. However, current levels of IT ... to recent efforts from policy makers to integrate IT ... found, through two different studies, that the current level ...
Cached Medicine News:Health News:DuPont and TERI Sign Memorandum of Understanding on Green Building Design in India 2Health News:DuPont and TERI Sign Memorandum of Understanding on Green Building Design in India 3Health News:DuPont and TERI Sign Memorandum of Understanding on Green Building Design in India 4Health News:Precision Therapeutics Adds 8 Million Covered Lives Under Contract 2Health News:Be in the Captain's Seat in the Fight Against Cancer 2Health News:Be in the Captain's Seat in the Fight Against Cancer 3Health News:Food as Medicine? 2Health News:Food as Medicine? 3Health News:Food as Medicine? 4Health News:Use of information technology is minimal in nursing homes 2
The MESACUP ANA Test Kit is a semi-quantitative enzyme-linked immunosorbent assay,(ELISA) for the detection of specific anti-nuclear antibodies in human serum as an aid in,the determination of autoim...
... Immuno Concepts manufactures slides that are compatible ... to decrease the number of pipetting steps ... sample dilutions on the slides. Ask Immuno ... and these slides. These slide formats are ...
... patented HEp-2 cell line that has been ... SS-A/Ro autoantibodies, without affecting the other ANA ... published worldwide on the HEp-2000 ANA substrate, ... when used in place of standard HEp-2 ...
... patented HEp-2 cell line that has been ... SS-A/Ro autoantibodies, without affecting the other ANA ... published worldwide on the HEp-2000 ANA substrate, ... when used in place of standard HEp-2 ...
Medicine Products: